Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Kiromic Biopharma, Inc. incurred senior notes of $2,400,000 with an accredited investor at 25% per annum maturing September 27, 2024.
- Instrument
- senior notes
- Principal
- $2,400,000
- Counterparty
- an accredited investor
- Rate
- 25% per annum
- Maturity
- September 27, 2024
- Event
- incurrence
Exact text from the filing
2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,400,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on September 27, 2024 (the “Maturity Date”), on which the principal balance and accrued but unpaid
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Kiromic Biopharma, Inc. entered into Note with an accredited investor valued at $2,400,000 (effective 2023-09-27).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- an accredited investor
- Value
- $2,400,000
- Effective
- 2023-09-27
Exact text from the filing
On September 27, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,400,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on September 27, 2024 (the “Maturity Date”), on which the principal balance and accrued but unpaid interest under the Note shall be due and payable.
View on SEC.gov